Understanding how a specific protein affects nerve development and degeneration
Elucidating the neural specific functions of the RNA-binding protein Caper in neural development and neurodegeneration
This study is looking at a protein called Caper to see how changes in it might affect the nervous system as we age and how it could be linked to conditions like ALS and Fragile X Syndrome, using fruit flies to help us understand what happens in our nerve cells.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Colorado Springs, United States) |
| Project ID | NIH-10577059 on NIH RePORTER |
What this research studies
This research investigates the role of the RNA-binding protein Caper in the development and aging of the nervous system. It focuses on how mutations in this protein can lead to neurological disorders such as amyotrophic lateral sclerosis and Fragile X Syndrome. By using a model organism, the fruit fly, the researchers aim to uncover the mechanisms by which Caper regulates RNA in nerve cells. The findings could provide insights into how similar processes occur in humans, particularly in relation to neurodegeneration.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are affected by neurological disorders such as amyotrophic lateral sclerosis or Fragile X Syndrome.
Not a fit: Patients with neurological conditions unrelated to RNA-binding protein dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating neurological disorders linked to RNA-binding protein dysfunction.
How similar studies have performed: Other research has shown promising results in understanding the roles of RNA-binding proteins in neurological diseases, suggesting that this approach has potential for success.
Where this research is happening
Colorado Springs, United States
- University of Colorado — Colorado Springs, United States (Active)
Researchers
- Principal investigator: Olesnicky, Eugenia C — University of Colorado
- Study coordinator: Olesnicky, Eugenia C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.